Purpose:To evaluate the effects of thymosin α1 (Tα1) in chemotherapy of NSCLC. Methods:We have conducted a prospective randomized controlled clinical trial.40 non-treated cases of stage Ⅲ-Ⅳ NSCLC were randomized into Tα1 group ( chemotherapy combined with thymosin α1) and control group (chemotherapy alone). The number of T cell subgroups, the activity of NK cell and phagocytic index of neutrophilic granulocyte in peripheral blood were detected and quality of life and changes of cancer lesions were evaluated before and after treatment. Results:After treatment,the levels of CD4 in the Tα1 group was significantly higher than before treatment(P0.05). After treatment,the natural killer(NK) activity in the control group was significantly lower than before treatment(P0.05). After chemotherapy, phagocytic index of the Tα1 group was significantly higher than that of the control group(P0.05).Overall response rate was 50% in the Tα1 group and 35% in the control group, but there was no statistically significant difference(P0.05). There was no significant difference of myelosuppression between the two groups. No infections or severe toxicity occurred in the Tα1 group. One severe lung infection was seen in the control group.There was better quality of life for the Tα1 group compared with the control group(P0.05). Prognosis of the Tα1 group was better than that of the control group. MST was 22.1 months in the Tα1 group and 12.0 months in the control group.1-year survival for the Tα1 group and the control group was 84.21% and 50.00%, respectively. 3-year survival for the Tα1 group and the control group was 27.72% and 14.29%, respectively. Conclusions:The immunological function of NSCLC is significantly elevated by Tα1 treatment. This trial indicates that chemotherapy combined with thymosin α1 for the treatment of NSCLC can improve patients’ quality of life and prolong survival.